MyMD Pharmaceuticals Inc (MYMD)

[knuts4oe]

MyMD's 6th Path To Success
This Path relates to the Akers Biosciences / Premas Biotech Covid 19 vaccine!
History - When Akers was an independent company it contracted with Premas Biotech of India for a Covid 19 vaccine, and Premas delivered with a trivalent Covid 19 vaccine. With the merger of MyMD and Akers the vaccine became a part of the new public MyMD Pharmaceuticals Inc. MyMD then joined with Oramed Pharmaceuticals to form Oravax Medical, a company focussed on vaccines in pill form, owned 13% by MyMD and 87% by Oramed, and assigned to it the RIGHTS to the Premas vaccine.
The Covid 19 vaccine developed by Premas is a trivalent vaccine, targeting 3 proteins on the Covid molecule, unlike the Pfizer and Moderna vaccines which target only the "spike" protein. This makes the Premas vaccine a much stronger vaccine against any variants that may develope.
Oravax has since licensed Premas to develope a injectable version of the vaccine for use in India. Sales of the injectable there, and sales of the pill form which is easily shipped anywhere, needs only normal refridgeration, and does not require medical personnel to administer it, would likely be a huge seller producing huge royalties.